Skip to main content

Table 4 Antiviral treatment

From: Influenza virus-related critical illness: prevention, diagnosis, treatment

Antiviral agents and age group [64]Treatment dosing
Oseltamivir
 Adults (including pregnancy)75 mg twice daily
 Children (1 year or older) ≤15 kg30 mg twice daily
 Children > 15–23 kg45 mg twice daily
 Children > 23–40 kg60 mg twice daily
 Children > 40 kg75 mg twice daily
 Term Infants 0–11 months*See details in footnote
 Preterm infants**See details in footnote
Zanamivir
 Adults10 mg (two 5-mg inhalations), twice daily
 Children (≥ 7 years)10 mg (two 5-mg inhalations), twice daily
Peramivir
 Adults600 mg intravenous infusion once, given over 15–30 min
 Children (2–12 years)One 12 mg/kg dose, up to 600 mg maximum, intravenous, given over 15–30 min
 Children (13–17 years)600 mg intravenous infusion once, given over 15–30 min
Baloxavir marboxil***
 Adults and children (12 years or older) ≥40–80 kgSingle dose of 40 mg
 Adults and children (12 years or older) ≥80 kgSingle dose of 80 mg
  1. *FDA-approved oral oseltamivir treatment dose for infants 14 days and older and less than 1 year old is 3 mg/kg per dose twice daily. The American Academy of Pediatrics has recommended an oseltamivir treatment dose of 3.5 mg/kg orally twice daily for infants 9–11 months of age
  2. **Current weight-based dosing recommendations are not appropriate for premature infants. Please refer to American Academy of Pediatrics recommendations (https://pediatrics.aappublications.org/content/142/4/e20182367) for further information
  3. ***Safety and efficacy of baloxavir marboxil in patients less than 12 years old or weighing less than 40 kg have not been established. There are no data on balosavir treatment of hospitalized patients with influenza, and appropriate dosing frequency is unknown. A phase III clinical trial of baloxavir treatment of hospitalized influenza patients is ongoing: https://clinicaltrials.gov/ct2/show/NCT03684044